Loading clinical trials...
Loading clinical trials...
The study aims to examine whether the combination of Lopinavir/Ritonavir plus Ribavirin for treatment of severe acute respiratory syndrome (SARS) is superior to placebo.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Hospital Authority, Hong Kong
NCT05543616 · SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, and more
NCT04516811 · COVID-19, SARS-CoV-2 Infection, and more
NCT04402879 · Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19, and more
NCT06409663 · Severe Acute Respiratory Syndrome Coronavirus 2 Infection
NCT04402957 · COVID, Severe Acute Respiratory Syndrome, and more
Department of Health
Hong Kong
Kowloon Hospital
Hong Kong
Prince of Wales Hospital
Hong Kong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions